Company Filing History:
4 out of 5 
1 out of 2,490 
1 out of 1,979 
Years Active: 2005-2019
Title: **Innovator Rashid Syed: Pioneering Anti-Tumor Therapies**
Introduction
Rashid Syed is an accomplished inventor based in Thousand Oaks, California. With a remarkable portfolio comprising five patents, Syed has significantly contributed to the field of biopharmaceuticals, particularly focusing on innovative therapies for cancer treatment.
Latest Patents
Syed's latest patents include groundbreaking work on engineered antibody-interferon mutant fusion molecules. This invention centers around genetically engineered fusion molecules that utilize a tumor-associated antigen (TAA) antibody to deliver cytokines directly to tumor cells, aiming to effectively inhibit their growth. The engineered Ab-interferon-alpha mutant fusion molecules have shown improved therapeutic indices and enhanced efficacy over traditional antibody-wildtype interferon fusion molecules.
Another notable patent of Syed involves engineered TAA antibody-tumor necrosis factor superfamily (TNFSF) member ligand fusion molecules. This invention integrates antibodies capable of targeting tumor cells with biologic moieties that induce apoptosis. Such engineered fusion molecules maintain their death-inducing effects while minimizing systemic toxicities, allowing for a more effective treatment option.
Career Highlights
Throughout his career, Rashid Syed has held impactful positions at esteemed organizations such as Immungene Inc and Columbia University in the City of New York. His work reflects a dedication to advancing cancer therapies through innovative research and development.
Collaborations
In his innovative journey, Syed has collaborated with notable professionals, including Iqbal Grewal and Sanjay Khare. These partnerships have likely facilitated the integration of diverse perspectives and expertise, leading to the advancement of Syed's pioneering discoveries.
Conclusion
Rashid Syed stands out as a visionary inventor, leveraging his expertise to develop transformative solutions in anti-tumor therapies. With his significant contributions captured in multiple patents, he continues to play a crucial role in the evolution of biopharmaceutical innovations aimed at enhancing cancer treatment outcomes.